Anne-Marie Carbonell, MD
Founder, CEO & Chief Medical Officer

Dr. Carbonell received her MD from St. Louis University (AOA, 1st in class) and trained in neurosurgery at the Cleveland Clinic. Prior to OncoSynergy, she gained valuable experience at MicroVention®, where she led pivotal trials at 35 clinical sites ultimately leading to FDA approval of 2 intracranial stents for treatment of brain aneurysms. At OncoSynergy, she translated decades of bench work into a manufactured product and successfully led FDA approval for our lead indication, glioblastoma. Leveraging her unique dual perspective as a clinician and patient, Dr. Carbonell leads OncoSynergy’s Phase I trial at Moffitt Cancer Center. Dr. Carbonell’s goal is to keep OncoSynergy at the forefront of translational science, medicine, and technology. She does so in part through her role as Principal Investigator on 2 active NIH grants, through active involvement in the Society of Neuro-oncology, and as a Senior Healthcare & Pharmaceutical Advisor to Ever Network (a Digital Health Company).

W. Shawn Carbonell, PhD, MD
Chief Scientific Officer

Dr. Carbonell earned his MD and PhD in Neuroscience from the University of Virginia through the NIH-funded Medical Scientist Training Program (MSTP), where he was honored as a Dean’s Merit Scholar. In 2009, he began his neurosurgery residency at Cedars-Sinai Medical Center. Currently, as Chief Scientific Officer at OncoSynergy, Dr. Carbonell oversees the company’s Research and Development Program, including the advancement of OS2966 and other assets. Before founding OncoSynergy, he completed two postdoctoral fellowships in neuro-oncology at the University of Oxford and UCSF. In 2019, Dr. Carbonell co-founded and became President of CureGlioblastoma, a 501(c)(3) nonprofit startup. As a physician-scientist-entrepreneur, Dr. Carbonell is dedicated to driving breakthroughs in the life sciences community.

Ambar Picon, ACRP-CP
VP of Corporate/Clinical Operations

Ms. Picon has extensive experience working hand in hand with C-suite and expertise in integrating efficient processes to position company operations for venture success. She takes pride in her keen process-oriented solutions and proactively problem-solving. Ms. Picon’s leadership has empowered our virtual, capital efficient business model. She also plays an active role in coaching team members, instilling key corporate values and concepts critical to OncoSynergy’s success. Ms. Picon’s background includes pre-medical studies and supporting top doctors and managing partners at private medical offices, gaining her valuable patient care experience. Frustrated with inefficiencies negatively affecting workflow and patient care, she implemented streamline operations which reduced costs and recovered money left on the table.  Self-driven and passionate about making an impact in areas of unmet needs, Ms. Picon joined OncoSynergy’s mission in 2019 and has quickly become a rising star within our team.

Gregory Wilson, MBA
Consulting CFO

Mr. Wilson received his MBA in Accounting from the University of Colorado and a BS in Biological Science from Colorado State University. He has more than 30 years’ experience in a variety of companies ranging from start-up to Fortune 500, public to private, and domestic to international. Prior to consulting, he was CFO at Micronics Computers (acquired by Diamond Multimedia) and Dyamics Isolation Systems (acquired by Berwind). Mr. Wilson’s early finance career stems with Gates Corporation, the majority owner of LearJet.

Our team is growing.
Job opening coming soon!

Our team is growing.
Job opening coming soon!